Protein Biomarkers in Major Depressive Disorder: An Update.

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Major Depressive Disorder (MDD) affects many, with limited treatment efficacy for some.
• Current MDD diagnosis relies on behavioral observation, lacking objective biological markers.
• Objective biomarkers are crucial for accurate MDD diagnosis and personalized treatment.

Purpose of the Study:

• To explore the potential of proteomic analysis for identifying MDD biomarkers.
• To highlight the utility of mass spectrometry (MS) in biomarker discovery for MDD.
• To emphasize the need for validated biomarkers for improved MDD diagnosis and treatment response prediction.

Main Methods:

• Utilizing mass spectrometry (MS) for comprehensive proteomic analysis of human biomaterials.
• Complementing MS with directed protein measurements like Western Blotting.
• Reviewing prior studies on MS-based proteomic analysis in various human samples (brain, CSF, blood, urine) for MDD.

Main Results:

• Proteomic analysis, particularly MS, is an underexplored yet powerful method for MDD biomarker research.
• Previous studies have applied MS to diverse human samples, yielding preliminary proteomic data in MDD.
• A significant gap exists in the validation and clinical application of identified proteomic biomarkers for MDD.

Conclusions:

• Further research employing MS and proteomic analysis is essential for establishing reliable MDD biomarkers.
• Validated biomarkers could revolutionize MDD diagnosis, treatment targeting, and understanding.
• Development of convenient, cost-effective predictive tests for depression treatment response is a critical goal.